Medlab Clinical Limited (MDC) 2016年年度报告「ASX」.pdf

1、MEDLAB CLINICAL LIMITED(ABN 51 169 149 071)ANNUAL REPORTFOR THE YEAR ENDED 30 JUNE 2016Copyright Medlab Clinical Ltd 2016INNOVATION-QUALITY-LIFE SCIENCESINNOVATION-QUALITY-LIFE SCIENCESNANOCELLE APPLICATION FOR MAJOR OFF-PATENT DRUG USEThe preliminary data from Phase 0 human trials on NanoCelle Ator

2、vastatin spray have beensuccessful.The data shows significant absorption from after 1 minute of spray use.Managementis progressing with accelerated human trials.Atorvastatin(Lipitor)(1232015ATO)NanoCelledSize 89.31 nmConc.0.1 mg/mLPreservatives inc.Atorvastatin(Lipitor)(12142015ATO30)NanoCelledSize

3、14.37 nmConc.1.67 mg/mLPreservatives inc.Atorvastatin(Lipitor)(12142015ATO25)NanoCelledSize 14.62nmConc.10 mg/mLPreservatives inc.Atorvastatin(Lipitor)Crystal sedimentationin waterAtorvastatin(Lipitor)(102015ATO)NanoCelledSize 11.41nmConc.Mg/mLCONTENTSmedlab.coINNOVATION-QUALITY-LIFE SCIENCESChairma

4、ns Letter4CEO Report5Directors Report9Auditors Independence Declaration18Financial Statements19Directors Declaration46Independent Auditors Report47Shareholder Information49Corporate Directory51 3 medlab.coINNOVATION-QUALITY-LIFE SCIENCES 4 CHAIRMANS LETTEROn behalf of the Board of Medlab Clinical Li

5、mited(Medlab),I am pleased to present our 2016 Annual Report.It is just over a year since our listing on the ASX and in that time a lot has been achieved.We are very proudwith what we have accomplished in such a short period of time.By placing an extra focus on the researchprogrammes,we have been ab

6、le to successfully advance our research significantly ahead of schedule(insome cases 12 to 18 month(e.g.)cannabis).In summary,some of our achievements in our research are as follows:Our patented NanoCelle small particle delivery system has so far delivered encouraging results,especially so in our pa